A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris Clinical Trial

Official title:

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02535871
• Other study ID #: V01-121A-302
• Status: Not yet recruiting
• Phase: Phase 3
• First received: August 26, 2015
• Last updated: September 11, 2015
• Start date: September 2015
• Est. completion date: July 2016

Study information

• Verified date: September 2015
• Source: Valeant Pharmaceuticals
• Contact: Anya Loncaric, MS
• Phone: 510-259-5284
• Email: aloncaric[@]solta.com
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare the efficacy, safety and tolerability of IDP-121 Lotion and vehicle in the treatment of subjects with acne vulgaris.

Description:

This is a multicenter, randomized, double-blind, parallel group, vehicle-controlled, 12-week study to evaluate relative changes in inflammatory and non-inflammatory lesion counts, as well as treatment success using an Evaluator's Global Severity Scale (EGSS) in subjects with moderate to severe acne. IDP-121 is a lotion for the topical treatment of acne.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 800
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 9 Years and older

Eligibility

Inclusion Criteria:

• Male or female at least 9 years of age and older

• Written and verbal informed consent must be obtained.

• Subject must have a score moderate or severe on the Evaluator's Global Severity assessment at the screening and baseline visit

• Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits

• Subjects must be willing to comply with study instructions and return to the clinic for required visits.

Exclusion Criteria:

• Any dermatological conditions on the face that could interfere with clinical evaluations

• Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive

• Subjects with a facial beard or mustache that could interfere with the study assessments

• Concomitant use of potentially irritating over-the-counter products

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Drug:
• IDP-121 Lotion
Investigational Product: IDP-121 Lotion
• IDP-121 Vehicle Lotion
Comparator Product: IDP-121 Vehicle Lotion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Valeant Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute change in inflammatory lesion count from baseline to Week 12	At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and nodules) on the subject's face.; Inflammatory lesions are defined as follows: Papule - a small, solid elevation less than 5 mm in diameter. Most of the lesion is above the surface of the skin.; Pustule - a small, circumscribed elevation less than 5 mm in diameter that contains yellow-white exudate.; Nodule - a subcutaneous lesion greater than or equal to 5 mm in diameter.	12 weeks	No
Primary	Absolute change in non-inflammatory lesion count from baseline to Week 12	At each visit the Evaluator will count the total number of non-inflammatory lesions (open and closed comedones).; Non-inflammatory lesions are defined as follows: Open comedones (black head) - a lesion in which the follicle opening is widely dilated with the contents protruding out onto the surface of the skin.; Closed comedones (white head)- a lesion in which the follicle opening is closed, but the sebaceous gland is enlarged by the pressure of the sebum build up, which in turn causes the skin around the follicle to thin and become elevated with a white appearance.	12 weeks	No
Primary	Proportion of subjects who have a least a 2 grade reduction at Week 12 from baseline in the Evaluator's Global Severity Score and were Clear or Almost Clear	At each visit the severity will be determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations will be scored on a scale of 0-4 (Evaluator's Global Severity Score), with 0 being clear and 4 being severe. Please see below for complete definitions.; 0 - Clear - Normal, clear skin with no evidence of acne vulgaris; Almost clear- Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red); Mild- Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions); Moderate-Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulo-cystic lesion; Severe- Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulo-cystic lesions.	12 weeks	No
Secondary	Percent change in inflammatory lesion count from baseline to Week 4, 8, and 12	At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and nodules) on the subject's face, and the percent change will be calculated.	4, 8, and 12 weeks	No
Secondary	Percent change in non-inflammatory lesion count from baseline to Week 4, 8, and 12	At each visit the Evaluator will count the total number of non-inflammatory lesions (open and closed comedones), and the percent change will be calculated.	4, 8, and 12 weeks	No
Secondary	Proportion of subjects who have a least a 2 grade reduction at Week 4, 8, and 12 from baseline in the Evaluator's Global Severity Score	At each visit the severity will be determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations will be scored on a scale of 0-4 (Evaluator's Global Severity Score), with 0 being clear and 4 being severe. Please see below for complete definitions.; 0 - Clear - Normal, clear skin with no evidence of acne vulgaris; Almost clear- Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red); Mild- Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions); Moderate-Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulo-cystic lesion; Severe- Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulo-cystic lesions.	4, 8, and 12 weeks	No